KER-065 is under clinical development by Keros Therapeutics and currently in Phase I for Obesity. According to GlobalData, Phase I drugs for Obesity have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KER-065’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KER-065 is under development for the treatment of Duchenne muscular dystrophy and obesity. The drug candidate is a protein which is an engineered ligand trap comprised of a modified ligand-binding domain derived from ActRIIA and ActRIIB that is fused to the portion of the human antibody known as the Fc domain and acts by targeting TGF beta ligand, including myostatin (GDF8), and activin A. It is administered through subcutaneous route.
Keros Therapeutics overview
Keros Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company’s product pipeline includes KER-050 for the treatment of low blood cell counts, cytopenias, including anemia and thrombocytopenia for patients with myelodysplastic syndrome (MDS) and myelofibrosis (MF); KER-047 for treating functional iron deficiency (FID) anemia in MDS and myelofibrosis (MF). Its pipeline also includes KER-012 to treat pulmonary arterial hypertension and chronic heart failure with preserved ejection fraction; and KER-065 to treat duchenne muscular dystrophy. The company is developing other drug programs which are at pre-clinical stage in areas of musculoskeletal disorders. Keros Therapeutics is headquartered in Lexington, Massachusetts, the US.
For a complete picture of KER-065’s drug-specific PTSR and LoA scores, buy the report here.